双参数前列腺磁共振成像的经济影响
该研究通过建模比较双参数MRI(BP-MRI)与多参数MRI(MP-MRI)的成本,发现在45分钟时间窗内进行3次完整BP-MRI的毛利润为1531.32美元,较MP-MRI增加892.58美元,相当于9小时工作日增加10710.98美元。作者认为BP-MRI在诊断流程中具有显著成本效益并增加可及性。
要点
- 在45分钟时间窗内,BP-MRI毛利润为1531.32美元,较MP-MRI增加892.58美元。
- 按9小时工作日计算,BP-MRI较MP-MRI增加毛利润10710.98美元。
- 作者认为BP-MRI在诊断流程中具有显著成本效益并增加MRI可及性。
核心结论
- 与传统MP-MRI相比,BP-MRI在前列腺癌诊断流程和风险分层中可能带来显著的成本效益并增加MRI可及性。
研究设计与样本
- 该研究通过建模比较BP-MRI与MP-MRI的潜在成本,以确定消除DCE序列可节省的费用。
主要发现
- 在允许一次完整MP-MRI或三次完整BP-MRI的45分钟时间窗内,BP-MRI毛利润为1531.32美元。
- 在45分钟时间窗内,BP-MRI较MP-MRI毛利润增加892.58美元。
- 在9小时工作日中,BP-MRI较MP-MRI毛利润增加10710.98美元。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric magnetic resonance imaging (MP-MRI) targeted biopsy has been shown to identify more clinically-significant cancers and reduce the detection of clinically-insignificant disease when compared to systematic biopsy; however, the wide-spread accessibility of MP-MRI is limited. A potential strategy for reducing the cost, study time, and contrast-associated risks associated with MP-MRI is elimination of the dynamic contrast-enhanced (DCE) sequence, relying instead on biparametric MRI (BP-MRI). BP-MRI has been shown to have a diagnostic accuracy and cancer detection rate that are equivalent to those of MP-MRI. METHODS: We modeled the potential cost of BP-MRI compared to MP-MRI to determine what cost savings would occur if DCE was eliminated from these studies. RESULTS: When controlled for a 45 min time window that allows for one full MP-MRI or three full BP-MRI studies, the BP-MRI 45 min gross profit is $1531.32. This is an increase in gross profit of $892.58 for the 45 min time window or $10,710.98 in a 9-h business day when performing BP-MRI compared to MP-MRI for prostate cancer detection. CONCLUSIONS: BP-MRI has the potential to result in substantial cost benefit and increased access to MRI in the diagnostic workflow and risk-stratification of men being evaluated for prostate cancer when compared to conventional MP-MRI.
引用
- Porter KK, King A, Galgano SJ, et al. Financial implications of biparametric prostate MRI. Prostate Cancer Prostatic Dis. 2019. PMID: 31239513. doi:10.1038/s41391-019-0158-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。